Pharmaceutical design of antimitotic agents based on combretastatins

H. P. Hsieh, J. P. Liou, N. Mahindroo

研究成果: 雜誌貢獻文章同行評審

160 引文 斯高帕斯(Scopus)

摘要

The design of novel anticancer agents based on the combretastatins, a group of antimitotic agents isolated from the bark of the South African willow tree Combretum caffrum Kuntz, is of considerable contemporary interest. Combretastatin A-4, the most active compound in the group, due to its unique dual features of antitubulin and antivascular properties, has drawn significant attention of medicinal chemists for the design of analogues as novel antitumor agents. To date, 252 references have been published since 1982 and 187 references have been published since 1998 related to combretastatins research. The 102 references related to chemistry efforts can be classified into three different categories including one-atom, two-atom, and three-atom bridgeheads as linker between two aryl rings of combretastatins. This review will particularly elucidate the rationale and strategic tactics towards the development of novel classes of antimitotic agents, based upon combretastatin A-4 as a promising lead.

原文英語
頁(從 - 到)1655-1677
頁數23
期刊Current Pharmaceutical Design
11
發行號13
DOIs
出版狀態已發佈 - 2005
對外發佈

ASJC Scopus subject areas

  • 分子醫學
  • 藥理學、毒理學和藥劑學 (全部)

指紋

深入研究「Pharmaceutical design of antimitotic agents based on combretastatins」主題。共同形成了獨特的指紋。

引用此